[Cis-dichlorodiammineplatinum, adriamycin and cyclophosphamide versus cis-dichlorodiammineplatinum, adriamycin, cyclophosphamide and CCNU in non-small cell carcinoma of the lung].
D000230:Adenocarcinoma / Q000188:drug therapy*; D002282:Adenocarcinoma, Bronchiolo-Alveolar / Q000188:drug therapy*; D000328:Adult; D000368:Aged; D018288:Carcinoma, Small Cell / Q000188:drug therapy*; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy*; D002945:Cisplatin / Q000008:administration & dosage*; D002986:Clinical Trials as Topic; D003520:Cyclophosphamide / Q000008:administration & dosage*; D004317:Doxorubicin / Q000008:administration & dosage*; D004359:Drug Therapy, Combination; D006801:Humans; D008130:Lomustine / Q000008:administration & dosage*; D008175:Lung Neoplasms / Q000188:drug therapy*; D008875:Middle Aged; D009607:Nitrosourea Compounds / Q000008:administration & dosage*
D009607:Nitrosourea Compounds; D008130:Lomustine; D004317:Doxorubicin; D003520:Cyclophosphamide; D002945:Cisplatin
Cis-diclorodiaminoplatino, adriamicina y ciclofosfamida frente a cis-diclorodiaminoplatino, adriamicina, ciclofosfamida y CCNU, en el carcinoma pulmonar no microcítico.